Your browser doesn't support javascript.
loading
Compatibility and stability of valsartan in a solid pharmaceutical formulation
Júlio, Tamíris Amanda; Zâmara, Igor Fernando; Garcia, Jerusa Simone; Trevisan, Marcello Garcia.
  • Júlio, Tamíris Amanda; Federal University of Alfenas. Institute of Chemistry. Laboratory of Pharmaceutical Analysis and Characterization. Alfenas. BR
  • Zâmara, Igor Fernando; Federal University of Alfenas. Institute of Chemistry. Laboratory of Pharmaceutical Analysis and Characterization. Alfenas. BR
  • Garcia, Jerusa Simone; Federal University of Alfenas. Institute of Chemistry. Laboratory of Pharmaceutical Analysis and Characterization. Alfenas. BR
  • Trevisan, Marcello Garcia; Federal University of Alfenas. Institute of Chemistry. Laboratory of Pharmaceutical Analysis and Characterization. Alfenas. BR
Braz. j. pharm. sci ; 49(4): 645-651, Oct.-Dec. 2013. ilus, tab
Article in English | LILACS | ID: lil-704095
ABSTRACT
Valsartan (VAL) is a highly selective blocker of the angiotensin II receptor that has been widely used in the treatment of hypertension. Active pharmaceutical ingredient compatibility with excipients (crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose and titanium dioxide) is usually evaluated in solid pharmaceutical development. Compatibility and stability can be evaluated by liquid chromatography. Studies were performed using binary mixtures of 11 (w/w) VAL/excipient; samples were stored under accelerated stability test conditions (40 ºC at 75% relative humidity). The results indicate that VAL is incompatible with crospovidone and hypromellose, which reduced the VAL content and gave rise to new peaks in the chromatogram due to degradation products.
RESUMO
Valsartana (VAL) é um bloqueador altamente seletivo do receptor da angiotensina II, que tem sido amplamente utilizado para o tratamento da hipertensão. Testes de compatibilidade com excipientes usualmente empregados em formulações sólidas são utilizados no desenvolvimento de formulações sólidas. Neste trabalho, realizaram-se testes utilizando misturas binárias na proporção 11 (m/m) de VAL/excipiente e as amostras foram armazenadas em condições de estabilidade acelerada (40 ºC em 75% de umidade relativa). Os resultados obtidos indicam a incompatibilidade de VAL com crospovidona e hipromelose, através da redução do teor de VAL e a presença de novos picos no cromatograma provenientes de produtos de degradação.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Chemistry, Pharmaceutical / Valsartan Language: English Journal: Braz. j. pharm. sci Year: 2013 Type: Article / Project document Affiliation country: Brazil Institution/Affiliation country: Federal University of Alfenas/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Chemistry, Pharmaceutical / Valsartan Language: English Journal: Braz. j. pharm. sci Year: 2013 Type: Article / Project document Affiliation country: Brazil Institution/Affiliation country: Federal University of Alfenas/BR